Should "atypical follicular cells" in thyroid fine-needle aspirates be subclassified?
Different types of "atypical follicular cells" have significantly different risks of malignancy. This disparity of risk should be communicated by the cytologist.
We demonstrate for the first time that the prevalence of cTnI-Abs in patients with AMI has an impact on the improvement of the LVEF over a study period of 6-9 months.